Dr Berend van der Wildt has in interest in the development of diagnostic and therapeutic radioligands for improved understanding of tumor biology and treatment of cancer, with a strong emphasis on neurooncology. Berend is specialized in organic chemistry, radiochemistry, and preclinical evaluation of novel radioactive compounds.